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Abstract
At a recent meeting (Sept 18, 2009) in which reasons for the limited access to artemisinin-based combination
therapy (ACT) in sub-Saharan Africa were discussed, policy and market surveys on anti-malarial drug availabil-
ity and accessibility in Burundi and Sierra Leone were presented in a highly interactive brainstorming session
among key stakeholders across private, public, and not-for-profit sectors. The surveys, the conduct of which
directly involved the national malaria control programme managers of the two countries, provides the
groundwork for evidence-based policy implementation. The results of the surveys could be extrapolated to
other countries with similar socio-demographic and malaria profiles. The meeting resulted in recommenda-
tions on key actions to be taken at the global, national, and community level for better ACT accessibility.
At the global level, both public and private sectors have actions to take to strengthen policies that lead to the
replacement of loose blister packs with fixed-dose ACT products, develop strategies to ban inappropriate anti-
malarials and regulate those bans, and facilitate technology and knowledge transfer to scale up production of
fixed-dose ACT products, which should be readily available and affordable to those patients who are in the great-
est need of these medicines.
At the national level, policies that regulate the anti-malarial medicines market should be enacted and enforced. The
public sector, including funding donors, should participate in ensuring that the private sector is engaged in the
ACT implementation process. Research similar to the surveys discussed is important for other countries to develop
and evaluate the right incentives at a local level.
At the community level, community outreach and education about appropriate preventive and treatment mea-
sures must continue and be strengthened, with service delivery systems developed within both public and
private sectors, among other measures, to decrease access to ineffective and inappropriate anti-malarial
medicines.
What was clear during the meeting is that continuing commitment, strengthened interaction and transparency
among various stakeholders, with focus on communities, national governments, and evidence-based policy and
action are the only way to sustainably address the control of malaria, a disease which continues to have a signifi-
cant health and socio-economic impact worldwide, particularly in sub-Saharan Africa.
Details on the methodology employed in carrying out the studies discussed at this meeting, as well as more
detailed results, data analysis and discussion of the studies are soon to be published.
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Background
Globally, 247 million clinical episodes of malaria are
estimated to occur every year, of which 86% are in sub-
Saharan Africa. Of more than 767,000 (5th-95th percen-
tiles: 621,000–902,000) Africans who are estimated to
have died from malaria in 2008, 88% were children
under five years of age, which equals to one child dying
of malaria every 45 seconds [1].
Access to artemisinin-based combination therapy
(ACT) is still limited in Africa, even though it has been
recommended by WHO since 2001 as the first-line
treatment for uncomplicated malaria [2]. Substantial
progress has been made in the past five years in the
number of sub-Saharan African countries that have now
adopted ACT as first-line treatment [3]. As of Septem-
ber 2009 [4], 81 countries have adopted ACT and 69
countries have deployed them (Figure 1).
However, access to appropriate anti-malarial drugs
remains inadequate as has been shown by recent house-
hold studies in several African countries [1]. Moreover,
scarce data exist on the availability (in terms of concen-
tration and pricing) of different forms of ACT in many
areas across sub-Saharan Africa.
To better understand where access is still limited, pol-
icy and market surveys on anti-malarial drug availability
and accessibility were done in selected countries where
the ACT artesunate and amodiaquine (AS+AQ) has
been adopted as first-line treatment of uncomplicated
Plasmodium falciparum malaria.
At the meeting organized and hosted by Drugs for
Neglected Disease initiative (DNDi) in Geneva, Switzer-
land, on Sept 18, 2009 (see Additional file 1), surveys
undertaken in Burundi from 1 to 16 March, 2009, and
Sierra Leone from May 24 to June 3, 2009, were pre-
sented by the lead investigative team of Dr. John
Amuasi (Research and Development Unit, the Komfo
Anokye Teaching Hospital [KATH], Ghana) and
Dr. Graciela Diap (DNDi, Geneva, Switzerland).
Results from these two surveys in sub-Saharan Africa
served as the launching point for a highly interactive
discussion among more than 30 experts from national
malaria control programmes (NMCPs) in Africa, WHO,
Roll Back Malaria (RBM), Health Action International
(HAI), UNITAID, The Global Fund, Medicines for
Malaria Venture (MMV), Malaria Consortium, sanofi-
aventis, Médecins-Sans-Frontières (MSF), Clinton HIV/
Figure 1 Countries adopting or deploying ACTs Reproduced, with permission, from http://www.who.int/malaria/publications/
treatment-policies/en/index.html.
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AIDS Initiative (CHAI), UNICEF, and Population Ser-
vices International (PSI).
Co-chaired by Dr. Olusoji Adeyi, the AMFm Unit
Director of The Global Fund to Fight AIDS, Tuberculo-
sis and Malaria, Dr. Angus Spiers, Regional Tuberculosis
and Malaria Advisor for UNICEF ESARO, Kenya, and
Dr. Bernard Pecoul, the Executive Director of DNDi, the
main objectives of the meeting were to:
• share results from the anti-malarial market (public
and private) and policy surveys in Burundi and
Sierra Leone;
• discuss how results from the Burundi and Sierra
Leone surveys could be used to optimize ACT distri-
bution at the community level, and through public
and private sector channels in Africa;
• discuss key issues to improve the rational use of
ACT;
• conceptualize areas of actions to facilitate deploy-
ment of ACT at the global, national, and community
level.
Although there is increasing interest in eliminating
malaria, there are also some countries at risk of being
left behind because of political instability, lack of Global
Fund eligibility, or disinterest/absence of pharmaceutical
industries within the country.
From the lessons of past experiences with the anti-
malarial chloroquine, the therapeutic life of ACT needs
to be reinforced at the community level [5]. To that
end, WHO policies to implement ACT include: preser-
vation of the useful therapeutic life of ACT, optimiza-
tion of ACT effectiveness, delay or prevention of
resistance, use of ACT of proven quality, and reclassifi-
cation of ACT to over-the-counter status (responsibly)
to ensure availability and accessibility.
Combination therapies for malaria are of public health
importance in Africa. It is, therefore, necessary that
ASAQ [6,7] the fixed-dose combination of AS+AQ, at a
no-profit/no-loss price launched by DNDi and sanofi-
aventis, and other combination therapies become rapidly
and widely accessible to patients who need it the most
in both rural and urban Africa. Currently, 25 African
countries are either undergoing the registration process
or have already registered ASAQ Winthrop®. Sanofi-
aventis reports that 12.6 million treatments of ASAQ
Winthrop® have been delivered to the public sector of
15 African countries between January and August 2009.
25–30 million treatments are forecasted to have been
delivered by the end of 2009, and 40–55 million treat-
ments will be delivered by the end of 2010. Those fore-
casts are thus far limited to the public sector. To assure
that there can be a successful implementation of ASAQ
in countries at risk of being left behind, DNDi and
KATH, together with the respective country’s NMCPs,
surveyed the current malaria market situation of Bur-
undi and Sierra Leone, where AS+AQ has been adopted
as first-line treatment for uncomplicated P. falciparum
malaria.
Methods for conducting the surveys
Adapted WHO-HAI methodologies [8] were used to
analyse data in public and private sectors. Data were
obtained by reviewing publications, interviewing relevant
health stakeholders, and visiting 70 retail drug outlets in
Burundi and 127 in Sierra Leone.
With WHO-HAI methodologies adapted for each
country, based on the uniqueness of the in-country
health systems, two strikingly different situations
emerged (Table 1).
Results of the surveys
Burundi
Burundi in the east African sub-region is one of the
smallest countries in Africa and has a population of
approximately 8.7 million people. Malaria remains a
Table 1 Surveys in a nutshell
Burundi - March 09
3 survey areas
Sierra Leone - June 09
6 survey areas
Malaria cases/year [1] 2.3 million 2.3 million
Population ~ 8.7 million ~ 6.4 million
Geographic area 27.830 km2 71.740 km2
Public & private outlets assessed 70 127
Availability of AS+AQ (as % of all types of outlets) 25.1% 30.9%
Median price of AS+AQ* Public: median – US$0.16(0.00–2.42)
Private: median – US$0.40 (0.17–2.82)
Public: median – US$1.56 (1.56-2.50)
Private: median – US$1.56 (0.16-6.25)
ACTs’ dispensers’ knowledge on indications for ACTs use 94% of public sector correct
Only 39% of private sector correct
71.9% of public sector correct
Only 15.9% of private sector correct
ASAQ Winthrop® registered Yes, delivered in March 2009 but not yet distributed† Process ongoing by October 2009†
*Presented as public/private and overall because of policy differences between countries.
†These data were obtained at the time of the meeting.
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major public health problem and is of great concern in
Burundi, where an epidemic during 2000–01 has
resulted in approximately 1,000 deaths every day over
the course of the epidemic [9,10]. Access to ACT
remains limited in Burundi where malaria is the leading
cause of infant deaths, being 47% of all deaths [11].
Burundi currently runs a three-tier healthcare admin-
istrative system — central, intermediate, and peripheral.
The central level determines the policy and strategy of
interventions, as well as the administration and quality
of the health system. The intermediate level recom-
mends policy to the cabinet and coordinates the imple-
mentation of policy within regions and sectors. The
peripheral level is composed of all the health centres
across the country. About 33% of all health centres are
privately owned, playing an important role in health-ser-
vice delivery [12].
Burundi has adopted AS+AQ combination therapy as
first-line therapy for the treatment of uncomplicated
malaria, and quinine tablets/injections for complicated
malaria as of December 2003, as its national anti-malar-
ial treatment policy. A fixed-dose formulation of ASAQ
Winthrop® has already been registered in Burundi for
public sector distribution, whereas for the private sector
(ASAQ brand name Coarsucam®) has not yet been
authorized for sale (Table 2). The NMCP and the Minis-
try of Health aim to have the same price for ACT in
both private and public sectors. The first orders
of ASAQ Winthrop® were placed for 1.7 million treat-
ments, costing up to US$1 million. In addition,
the Burundi Government continues to accept donations
of non-fixed-dose, non-prequalified AS+AQ. In the diffi-
cult-to-regulate private sector, an unauthorized system
runs in parallel to the formal structure of the drug dis-
tribution system in Burundi and includes an irrational
prescription of essential medicines.
In the public sector, the Government subsidizes each
treatment course of AS+AQ so that it costs 200 FBU
(US$0.16) to the patient. In addition, treatment is
offered free for children younger than five years of age.
At the time of the survey, there was no existing policy
on free treatment for children older than five years of
age. This was also the finding for pregnant women, for
whom quinine is the first-line treatment. However,
according to the NMCP, this policy has since changed
and pregnant women are now also eligible for the free
anti-malarial service.
Currently, The Global Fund and UNICEF procure
ACTs and rapid diagnostic tests for the NMCP. The
central medical store of the Ministry of Health stocks
quinine, which is self-procured. Anti-malarial drugs for
children under five years of age come mainly from The
Global Fund. It is planned that the proposed repackage
of ASAQ Winthrop® for provision at the same price to
the private market will be supported by 10% of The
Global Fund budget.
In Burundi, AS+AQ represented a quarter of the anti-
malarials surveyed (Table 2). Quinine tablets are the
most common anti-malarial drugs, and are equally pre-
sent across both public and private sectors. Quinine
injections also represented a quarter of the anti-malar-
ials surveyed. AS+AQ was more likely to be found in
the public (34.8%) than in the private sector (13.5%)
(p<0.001). Halofantrine, which is not part of the national
policy, was much more present in the private than in
the public sector (Table 2). This observation is alarming
because of potential adverse cardiac effects of halofan-
trine [13]. Its availability also leads to concerns about
the potential cross-resistance with lumefantrine (LUM)
and mefloquine (MQ) [14,15], which could also have a
devastating effect on the future deployment of arte-
mether (AR)+LUM and AS+MQ.
The median price of the recommended AS+AQ first-
line treatment was similar in the governmental and
charity sectors (US$0.16), and 2.5-fold higher in the pri-
vate sector (Table 3). The median price of quinine
Table 2 Availability of anti-malarial drugs in Burundi (70 outlets), by public and private sector
Number of anti-malarial drugs in
outlets surveyed (n=243)
Number of anti-malarial drugs in the
public sector (n=132)
Number of anti-malarial drugs in the
private sector (n=111)
Amodiaquine (AQ) 1 (0.4%) 0 1 (0.9%)
Artemether+lumefantrine
(AR+LUM)
3 (1.2%) 0 3 (2.7%)
Artesunate+amodiaquine
(AS+AQ)
61 (25.1%) 46 (34.8%) 15 (13.5%)
Dihydroartemisinin +
piperaquine (DHA+PQ)
1 (0.4%) 0 1 (0.9%)
Dihydroartemisinin (DHA) 4 (1.6%) 0 4 (3.6%)
Halofantrine 16 (6.6%) 2 (1.5%) 14 (12.6%)
Quinine injection 54 (22.2%) 29 (22.0%) 25 (22.5%)
Quinine tablets 103 (42.4%) 55 (41.7%) 48 (43.2%)
Data are n (%).
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tablets and injections was also higher in the private sec-
tor compared with that in public and charitable sectors.
Surprisingly, quinine is being used as first-line treatment
for uncomplicated malaria in both public and private
sectors, despite the fact that it is more expensive than
subsidized ACT. The reason for this could be that qui-
nine has been available for much longer and people are
more familiar with this drug than with ACT, or that
there could be a higher profit margin for quinine than
for ACT for the distributors.
Across all three surveyed regions (Bujumbura, Bururi
and Kayanza) and sectors in Burundi, more than 50% of
retailers were familiar with ACT, with the highest
knowledge in the charitable sector (90%) and the lowest
in the private sector (55%). Knowledge of WHO malaria
treatment and national guidelines was especially low in
the private sector and among consumers.
The following is a summary record of the question-
and-answer session that took place during the Burundi
survey presentation:
• What was the pricing of artesunate (AS) mono-
therapy, and how large was its market share?
Response: Average price was US$0.32, and it repre-
sented 1.6% of anti-malarials found within the sur-
vey. This price corresponds to a complete treatment
and is found only in the private sector.
• Is there a lot of variation in the pricing of ACTs in
the charitable sector?
Response: Although this was not expected because the
charitable sector should have the same free/subsidized
policy as the public sector, prices varied widely.
• Were anti-malarials really distributed for free for
children under five years of age and pregnant
women, and subsidized for the rest of the population
in the public sector?
Response: Yes.
• Do the vendors in the private sector influence or
bias the purchaser’s decision?
Response: Yes, but there are many confounding fac-
tors which may influence the purchaser’s posture and
the vendor’s influence, making this highly subjective.
• The public sector dispensor’s knowledge of ACT
was impressive compared with that of the private
sector. Was this influenced by ASAQ training?
Response: Since 2003, public training has been avail-
able for ACT implementation, but much less in the
private sector.
• Based on WHO-HAI methodology, the minimum
number of outlets is generally 120 to be surveyed,
why were only 70 outlets in Burundi?
Response: The number of outlets surveyed depended
on the density of the population and the size of the
country, and this was representative in the three
areas surveyed.
• What is the reward of the private pharmacists
when they distribute quinine rather than AS+AQ?
Response: ACTs were not widely available in the pri-
vate sector; if ACT were available; they were mostly
being smuggled into the country or leaked from the
public sector.
• Was it possible to differentiate retailers from
dispensers?
Table 3 Pricing of anti-malarial drugs in Burundi,
by sector






AS+AQ 31 0.16 (0.00–0.16)
Halofantrine 2 8.90 (8.35–9.44)
Quinine injection 20 0.24 (0.00–0.48)
Charity
AS+AQ 15 0.16 (0.08–2.42)
Quinine injection 9 0.32 (0.16–0.81)
Quinine tablets 1 1.66 (0.51–2.58)
Private
AQ 1 0.32 (0.32–0.32)
AM+LUM 2 0.60 (0.40–0.81)
AS+AQ 7 0.40 (0.17–2.82)
DHA+PQ 1 2.82 (2.82–2.82)
Dihydroartemisinin 1 4.84 (4.84–4.84)
Dihydroartemisinin* 3 4.03 (4.03–4.84)
Halofantrine 3 9.68 (8.47–9.68)
Halofantrine* 11 9.68 (7.66–11.29)
Quinine injection 17 0.40 (0.24–1.61)
Quinine tablets 29 1.61 (0.32–3.39)
For tablets the price is for a course; for injections is for a single injection. The
price per course is neither for adults nor for adolescents or children. Often
when an adult treatment is not available; multiple adolescent or child doses
are given to supplement and vice-versa.
*These were found in stand-alone pharmacies that were not attached to, or
part of, any health facility.
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Response: Not in these surveys – varying definitions
can make it difficult.
• Were products other than anti-malarials compared
on the market?
Response: No comparator drugs were used in the
surveys.
• Why was there a general preference for quinine?
Response: Quinine has been widely available for a long
time. Chloroquine was banned six years ago and was
not found on the market, which was reassuring.
Sierra Leone
Located on the west coast of Africa, Sierra Leone is a
small country where three-fourths of the population of
about 6.4 million people live below the poverty line of
US$1 per day, and where infant and maternal mortality
are among the highest in Africa. Access to ACTs is lim-
ited in Sierra Leone, where malaria is one of the leading
causes of morbidity and mortality.
In Sierra Leone, 77% of people can access primary
health services [16]. A visit to the formal health sector
can cost three times the average daily wage. Trained
health workers are lacking at all community levels, espe-
cially in rural areas. The healthcare system is poorly
used, with out-of-pocket expenses remaining one of the
highest in Africa (70%). The final drug cost to the patient
is 180% of the landed cost if it originated from the central
medical stores. There is a need to simplify the flow of
distribution of drugs to reduce the costs to the patient.
AS+AQ was adopted as first-line treatment for
uncomplicated malaria in 2004, after which a 25% drop
in malaria infection was observed over an ensuing five-
year period [17]. Anti-malarial drugs are available at all
healthcare facilities through the national Essential Drugs
programme, charitable and private sectors, and are pro-
vided free of charge in all public facilities by govern-
mental and the charitable sectors.
Currently, the NMCP is supported with US$10 mil-
lion from The Global Fund from June 2008 to May
2010, which represents 30.7% of its entire two-year
budget. To ensure correct distribution of the drugs, the
Home-Based Management of Malaria Initiative was
launched in 2007. Besides The Global Fund, UNICEF
runs a separate ACT procurement system, which is
mainly funded by the Japanese and German Govern-
ments. To fill the remaining gaps, the Government of
Sierra Leone (from internally generated funds) also
procures anti-malarials, mainly quinine, through cen-
tral malaria stores.
In April 2009, following poor drug forecasting, diffi-
culties in the distribution system and poor coordination
among key players, about 900,000 doses of AS+AQ were
destroyed, but shortages still existed at the market level,
indicating the need to streamline the procurement sys-
tem and coordinate these efforts. Further investigation is
needed to determine the cause behind the system’s fail-
ure at that time.
Of the 340 anti-malarials in the 127 outlets, only
30.9% were policy-recommended AS+AQ, 20% quinine,
and 20% sulphadoxine-pyrimethamine (SP). Surprisingly,
chloroquine formed 12.7% of the market.
Only 19 out of the 127 surveyed outlets (15.0%) car-
ried all three policy-recommended anti-malarials, with
the public sector performing best (57.9% carried all
three policy-recommended anti-malarials). About 86.7%
of the private outlets carried no policy-recommended
anti-malarials. AS+AQ was a third of the anti-malarials
in the surveyed outlets, and was the most common on
the market in all sectors, followed by SP (Table 4).
Chloroquine, quinine, and other monotherapies includ-
ing AS were still widely used as first-line treatment. The
distribution of drugs was mainly a push rather than a
pull system, and there was a weak control on their
importation.
About 50.8% of anti-malarial drugs were dispensed
over the counter. Chloroquine was mainly found over
the counter (87.7%) rather than prescription only,
whereas AS+AQ was accessible more often through pre-
scription only (67.2%).
AS+AQ had the highest median price of all anti-
malarials in the surveyed outlets (Table 5) and the low-
est in the charitable sector. Although it was supposed to
be free within the public sector, the median price was
US$1.56 (of the three outlets in which it was found).
Quinine injection prices were the same in the public
and charitable sectors and comparably higher in the pri-
vate sector, whereas quinine tablets were cheapest in the
public sector and increasingly more expensive in the
charitable and private sectors.
Across all six surveyed regions (Bo, Kalihun,
Kenema, Koinadugu, Port Loko and Western urban
area) and sectors high knowledge and familiarity with
ACT (>92%) were found in the governmental and
charitable sector compared with that in the private
sector (73%). In terms of WHO treatment recommen-
dations and national anti-malarial policy, the private
sector had the least knowledge (25–32% vs 54–61% for
the charitable sector and 87–89% for the public
sector).
The following is a summary record of the question-
and-answer session that took place during the Sierra
Leone survey presentation:
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• What was the price difference between the drug
store and the patent shops (defined by the Sierra
Leone Ministry of Health more like a licensed chemi-
cal seller outlet)
Response: The most expensive average price for
AS+AQ in the pharmacies was US$2.93, in the drug
stores US$1.88, and in patent shops US$0.35.
• In the methodology, what is proportion of the dif-
ferent sectors (private, public, charitable) represented
in the market share?
Response: In Sierra Leone, one needs to consider
the informal sector, particularly the Chinese ped-
dlers selling anti-malarials. In a government hospi-
tal, Chinese-made quinine injections that did not
have a manufacturer name. Samples were bought.
There are chloroquine tablets, combination of
chloroquine and paracetamol, chloroquine injec-
tions and syrup freely available in both private out-
lets (pharmacies and drug shops) and mission/
NGO hospitals. Drug peddlers move from village to
village selling drugs; particularly the Chinese. In
districts where the system is strong (such as in Bo),
they have been driven out. However, in most places
they are fully operational and selling anti-malarials
at will.
• How can donations be managed to reflect policy?
And how can policy be made to reflect donations?
Response: Many anti-malarials are coming from
donations and should be viewed with caution. Dona-
tions are being received, but decisions made by
high-level decision makers may take issues other
than policy into consideration.
• In Sierra Leone, was AS+AQ available in loose
dose or blister packs?
Response: Only blister packs were available for
AS+AQ. No loose doses were available.
Table 5 Pricing of anti-malarial drugs in Sierra Leone, by
sector






AS+AQ 3 1.56 (1.56–2.50)
Quinine injection 8 0.31 (0.16–0.94)
Quinine tablets 8 0.55 (0.31–0.94)
SP 4 0.31 (0.28–0.31)
Charity
AS+AQ 7 0.62 (0.31–5.31)
Quinine injection 8 0.31 (0.09–0.47)
Quinine tablets 9 0.62 (0.31–1.25)
SP 8 0.31 (0.16–0.47)
Chloroquine tablets 1 0.16 (0.16–0.16)
Private
AS+AQ 28 1.56 (0.16–6.25)
Quinine injection 8 0.47 (0.16–0.62)
Quinine tablets 8 0.95 (0.63–1.88)
SP 29 0.47 (0.31–0.94)
Chloroquine tablets 24 0.16 (0.09–1.25)
For tablets the price is for a course; for injections is for a single injection. The
price per course is neither for adults nor for adolescents or children. Often
when an adult treatment is not available; multiple adolescent or child doses
are given to supplement and vice-versa.
Table 4 Availability of anti-malarial drugs in Sierra Leone (127 outlets surveyed), by public, charitable and private
sectors
Number of anti-malarials in
outlets surveyed (n=340)




Number of anti-malarials in
the private sector(n=132)
AM+LUM 3 (0.9%) 0 1 (1.5%) 2 (1.5%)
AQ 8 (2.4%) 1 (0.7%) 1 (1.5%) 6 (4.5%)
AR 13 (3.8%) 3 (2.1%) 4 (6.0%) 6 (4.5%)
AS 15 (4.4%) 2 (1.4%) 3 (4.5%) 10 (7.6%)
AS+AQ 100 (29.4%) 55 (39.0%) 20 (29.9%) 25 (18.9%)
AS+MQ 1 (0.3%) 0 0 1 (0.8%)
AS+SP 6 (1.8%) 0 1 (1.5%) 5 (3.8%)
Chloroquine 35 (10.3%) 0 4 (6.0%) 31 (23.5%)
Halofantrine 3 (0.9%) 0 0 3 (2.3%)
MQ 3 (0.9%) 0 1 (1.5%) 2 (1.5%)
Proguanil 1 (0.3%) 0 0 1 (0.8%)
Pyrimethamine 1 (0.3%) 0 0 1 (0.8%)
Quinine 67 (19.7%) 36 (25.5%) 16 (23.9%) 15 (11.4%)
SP 84 (24.7%) 44 (31.2%) 16 (23.9%) 24 (18.2%)
Data are n (%).
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Discussion
The use of ACT should be considered as part of a big-
ger picture of malaria case management. The current
malaria treatment guidelines formulated by the WHO
[18] recommend parasite-based diagnosis for older chil-
dren and adults in all malarial settings and clinical diag-
nosis for children under five years of age in areas of
high transmission. Artemisinin-based combinations are
recommended for treatment of uncomplicated P. falci-
parum malaria in all age groups, except during the first
trimester of pregnancy [19].
Five formats of ACT are presently recommended: arte-
mether and lumefantrine, artesunate and amodiaquine,
artesunate and mefloquine, artesunate and sulfadoxine-
pyrimethamine, and dihydroartemisinin and piperaquine
(DHA-PQ). DHA-PQ, which has been added in 2009, is
not expected to make up a large part of the market
because of approval hurdles. The clinical profile of
malaria in an area determines the kind of health care ser-
vices needed. If the disease occurs mainly in children, the
system will focus on paediatric services. If the disease is
acute, rapidly progressing and fatal, the health care ser-
vices must be provided both at the level of the commu-
nity for early treatment and of tertiary institutions for
care for severe disease. In order to optimize the benefit
of artemisinin-based combination, treatments must be
available as widely as possible. Therefore, home manage-
ment of malaria should be implemented in areas where
there is poor access to health facilities, as the formal
public health delivery system will not reach many people
who need treatment. Distribution and use of ACT
depends on several factors including regulatory status,
ease of implementation, safety and other factors. WHO
provides recommendations and guidelines for countries
to reinforce implementation of ACT.
Proposed interventions
At the community level, trained community health
workers could deliver pre-packaged anti-malarial drugs
to children younger than five years of age. Specifically,
community health workers can be trained to recognise
symptoms of severity, and referred if needed, and be
trained to use rapid diagnostic tests to diagnose malaria
and deliver pre-packaged drugs to children. This system
has been successfully carried out in past studies in the
Zambia, Uganda, Cambodia, Mali, Chad, Sierra Leone,
south Sudan and Ethiopia [20-24]. Malaria care should
also be combined with management of other common
childhood illnesses (ie, pneumonia and diarrhoea).
Further evaluation of these interventions is needed.
Besides accessibility to services, accessibility to effec-
tive treatment is needed and requires effective integra-
tion into the health system. Accessibility to effective
treatment may require provision of incentives to reduce
attrition and improve performance with sustained com-
munity financing of central medicine distributors. Home
management for malaria may offer an alternative
malaria case management policy but will not be sustain-
able without a functioning health system.
There is a need to harmonize the work of all front-
line workers, including community health workers, cen-
tral medicine distributors and home management for
malaria who come from different backgrounds, as well
as traditional healers, to reduce non-adherence to
national policies and improve performance. By motivat-
ing and mobilizing these front-line workers, ACT imple-
mentation can be scaled up. However, an assessment of
what type of effective system is needed for support is
required. In addition, there are almost no examples of
adequate community financing for central medicine dis-
tributors; therefore, there is a need for consistent com-
munity and policy support to ensure the availability of
drugs to ensure the effective function of central medi-
cine distributors.
Key issues
The Burundi and Sierra Leone surveys highlight a lack
of, or weak enforcement of, regulation of importation of
anti-malarial drugs. In addition, involvement of the pri-
vate sector is missing in training, planning of delivery,
and poor quality of services that include: no diagnostics,
lack of knowledge of correct treatment regimes per
national and WHO policy, unnecessary treatment sales,
and high costs to the patient.
For widespread ACT implementation, the private sec-
tor needs to be acknowledged and engaged with imple-
mentation plans. By doing so, it will facilitate stopping
sales of non-recommended anti-malarials that include
monotherapies and fake drugs. A system should be put
in place and enforced so that those who sell unauthor-
ized anti-malarials are legally prosecuted. To provide
effective treatment, compulsory training programmes
could be launched for the private sector to improve
proper diagnosis, treatment and referral in severe cases.
Other options may include incentivizing or subsidizing
the costs of drugs sold in the private sector, making
them cheaper for the consumer. As a first step, it may
also be relevant to understand why consumers prefer to
go to the private sector to purchase their drugs rather
than to public sector facilities. In addition, consumers
need to be educated because the responsibility of correct
treatment does not lie only with the distributors but also
with the consumer themselves, which will demand high
quality and correct treatments.
As a pilot study, Uganda’s Ministry of Health, in colla-
boration with MMV, is evaluating the effects of ACT
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uptake by offering subsidized ACT to the private sector
[25]. Data were obtained from interviews, retail audit,
health facility audit, as well as household surveys.
Interim results show that subsidized ACT erode the
chloroquine market share for anti-malarial drugs for
children younger than five years of age, and subsidized
anti-malarial drugs now account for half of all anti-
malarials purchased for people over five years of age.
Similar research is needed in other countries to evalu-
ate different incentives to increase ACT uptake. To opti-
mize data collection and usefulness, methodologies
should be flexible yet robust to best meet the research
need and policy demands across different countries.
Outcomes
These surveys were carried out in two countries where
the communities were in hard-to-reach areas, which
mean these populations are often neglected because dif-
ficult to access. The studies directly involved the NMCP
project managers in the country: the value of the
obtained data and the key participation on NMCPs
could facilitate policy change and greater action for
widespread ACT implementation. The surveys provides
the groundwork for evidence-based policy implementa-
tion, which could be translated to other countries with
similar socio-demographic and malaria profiles.
Limitations of the studies include the subjectivity of
some of the questions used as well as selection bias of
the outlets given the short duration of the study period
(two weeks), with less than one hour spent at each of
the outlets surveyed. In addition, no drug was used for
comparison with the anti-malarials evaluated; therefore,
it is unclear whether the pricing, availability and afford-
ability of anti-malarials reflect the general situation of
all drugs distributed in the outlet or is specific for anti-
malarials. Lack of product quality assessment is an addi-
tional limitation of the study.
Recommendations
During the meeting, information sharing with various
key members provided great value for the participants
and for those conducting the research. Based on discus-
sions related to the outcomes from the Burundi and
Sierra Leone surveys, the meeting made the following
recommendations and proposed areas of actions at the
global, national, and community level for improved
ACT implementation.
Global actions
• Technology transfer to local manufacturers in sub-
Saharan Africa
• Development of a funding strategy to give prefer-
ence to fixed-dose combination ACT with a defined
time period to phase out non-fixed-dose combina-
tion ACT
• Development of a strategy to regulate banned arte-
minin-based combinations from entering into the
market
• Inclusion of education and training for all ACT
supply lines, emphasizing the private sector
• Formalization of all sectors (public, private, chari-
table, and informal) to reach widespread dissemina-
tion of ACT
• Possibility of a worldwide ban on the manufacture,
importation and sale of AS monotherapies
• Write to WHO Committee on Essential Medicine
List Selection to recommend issuing guidelines for
fixed-dose combination to remove the inclusion of
blister packages. If removed from the Essential Med-
icine List, the blister packages cannot be pre-quali-
fied and, therefore, will not be purchasable by
governments benefiting from the Global Fund
provisions.
National actions
• National policy should regulate the ACT market
• Private sector should be engaged in the ACT
implementation process: both donors and public sec-
tor must engage
• Possible incentives for private sector providers to
establish facilities in remote areas where ACT is dif-
ficult to access
• Establishment of ACT donation guidelines to
reflect national anti-malarial policy for donation pro-
grammes in the spirit of the WHO Guidelines for
Drug Donations
• Possible removal of tariffs before the taxes for
imported ACT
• Research similar to this is needed in other coun-
tries to evaluate different incentives to increase ACT
uptake
Community actions
• Education of the community about preventive and
treatment measures—bed nets and ACT
• Development of a service delivery system for diag-
nosis, treatment, and follow-up within both public
and private sectors
• Creation of a network for diagnosis and treatment
• Possible incentives for ACT distributors (i.e. com-
munity health workers) if ACT is to be disseminated
for free
• Transparency on how ACT is paid for in terms of
drug and service delivery
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• Development of a common framework to harmo-
nize the public, private and charitable sectors in
ACT implementation
• To decrease of access to “bad” drugs, availability
and affordability of effective treatment need to be
increased
• To ensure quality of treatment and management,
compliance measures should be improved
• Evaluation of an integrated approach for ACT
implementation that could include the role of the
community health worker with minimal training as
they have been effective in managing other diseases,
such as anti-retroviral treatment of HIV patients
• Further evaluation of these interventions are
needed
• Harmonization of the work of all frontline workers
• Similar research is needed in other countries to
evaluate different incentives to increase ACT uptake
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